REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$607.06

Market cap

$65.29B

P/E Ratio

9.16

Dividend/share

N/A

EPS

$66.28

Enterprise value

$64.55B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The company's EPS has surged by 128% YoY and by 13% QoQ
Regeneron Pharmaceuticals's net income has surged by 122% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.regeneron.com/
Peers: AMGN ALNY BIIB JNJ

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
107.54M
Market cap
$65.29B
Enterprise value
$64.55B
Valuations
Price to earnings (P/E)
9.16
Price to book (P/B)
3.76
Price to sales (P/S)
4.76
EV/EBIT
7.96
EV/EBITDA
7.7
EV/Sales
4.77
Earnings
Revenue
$13.54B
EBIT
$8.11B
EBITDA
$8.38B
Free cash flow
$5.38B
Per share
EPS
$66.28
Free cash flow per share
$50.67
Book value per share
$161.36
Revenue per share
$127.52
TBVPS
$222.9
Balance sheet
Total assets
$23.67B
Total liabilities
$6.41B
Debt
$2.7B
Equity
$17.26B
Working capital
$10.06B
Liquidity
Debt to equity
0.16
Current ratio
3.71
Quick ratio
3.03
Net debt/EBITDA
-0.09
Margins
EBITDA margin
61.9%
Gross margin
86.6%
Net margin
51.7%
Operating margin
55.2%
Efficiency
Return on assets
34.9%
Return on equity
50.5%
Return on invested capital
47.4%
Return on capital employed
40.6%
Return on sales
59.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
0.3%
1 week
-1.19%
1 month
-4.37%
1 year
17.75%
YTD
-3.87%
QTD
-3.87%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$13.54B
Gross profit
$11.73B
Operating income
$7.47B
Net income
$7B
Gross margin
86.6%
Net margin
51.7%
The operating income has soared by 142% YoY and by 12% QoQ
Regeneron Pharmaceuticals's net income has surged by 122% YoY and by 13% QoQ
The revenue has soared by 71% YoY and by 9% QoQ
Regeneron Pharmaceuticals's gross profit has soared by 69% YoY and by 9% from the previous quarter

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
9.16
P/B
3.76
P/S
4.76
EV/EBIT
7.96
EV/EBITDA
7.7
EV/Sales
4.77
The company's EPS has surged by 128% YoY and by 13% QoQ
REGN's price to earnings (P/E) is 59% lower than its 5-year quarterly average of 22.5 and 21% lower than its last 4 quarters average of 11.5
The equity has surged by 70% year-on-year and by 14% since the previous quarter
REGN's price to book (P/B) is 31% less than its 5-year quarterly average of 5.4 and 9% less than its last 4 quarters average of 4.1
The revenue has soared by 71% YoY and by 9% QoQ
The P/S is 32% lower than the 5-year quarterly average of 7.0 and 10% lower than the last 4 quarters average of 5.3

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has surged by 69% YoY
The return on assets has surged by 69% year-on-year and by 2% since the previous quarter
Regeneron Pharmaceuticals's return on invested capital has surged by 67% YoY and by 3.9% QoQ
The company's return on sales rose by 35% YoY

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
REGN's total assets is up by 47% year-on-year and by 10% since the previous quarter
Regeneron Pharmaceuticals's total liabilities has increased by 8% YoY
The debt is 84% less than the equity
The equity has surged by 70% year-on-year and by 14% since the previous quarter
REGN's debt to equity is down by 41% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.